VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Poor oral health (periodontal disease) impacts nearly 51% of Indians
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
The company will also share results in two additional posters for deuruxolitinib
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Pfizer's decision is based on the totality of clinical data
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
ALS patients experience neuroinflammation and rapid neurodegeneration
Subscribe To Our Newsletter & Stay Updated
